Differences
This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionBoth sides next revision | ||
pharmaceutical_companies:abcellera [2022/05/04 22:10] liam | pharmaceutical_companies:abcellera [2024/03/08 16:46] (current) liam | ||
---|---|---|---|
Line 4: | Line 4: | ||
**AbCellera** is a Canadian biotechnology company based in [[: | **AbCellera** is a Canadian biotechnology company based in [[: | ||
+ | |||
+ | ==== About ==== | ||
+ | |||
+ | AbCellera grew out of the idea that single-cell [[: | ||
+ | |||
+ | Our multidisciplinary team of cell biologists, biochemists, | ||
+ | |||
+ | Our impact is measured by the success of our partners and the advancement of [[:antibody therapies]]. We are motivated by the feeling that our days are being well spent. That our work really matters.((https:// | ||
===== Affiliations ===== | ===== Affiliations ===== | ||
AbCellera has partnered with a notable assortment of [[pharmaceutical companies]] and other interests, including [[Ablynx]], [[Autolus Therapeutics]], | AbCellera has partnered with a notable assortment of [[pharmaceutical companies]] and other interests, including [[Ablynx]], [[Autolus Therapeutics]], | ||
+ | |||
+ | The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA' | ||
+ | |||
+ | Subsidiaries: | ||
==== Bill & Melinda Gates Foundation ==== | ==== Bill & Melinda Gates Foundation ==== | ||
Line 23: | Line 35: | ||
==== DARPA ==== | ==== DARPA ==== | ||
- | In 2018, AbCellera received US$30.6 million from the Defense Advanced Research Projects Agency ([[DARPA]]) to lead one of four research groups aimed at developing antibody treatments for pandemics. | + | In 2018, AbCellera received US$30.6 million from the [[:Defense Advanced Research Projects Agency]] ([[:DARPA]]) to lead one of four research groups aimed at developing antibody treatments for pandemics.((Silcoff, S. (2020, December 11). //A Canadian biotech giant is born: AbCellera stock triples in debut, company now worth US$15-billion.// |
==== Eli Lilly ==== | ==== Eli Lilly ==== | ||
Line 32: | Line 43: | ||
A second COVID-19 monoclonal antibody therapy ([[: | A second COVID-19 monoclonal antibody therapy ([[: | ||
+ | |||
+ | ==== Board of Directors ==== | ||
+ | |||
+ | === Alexander Karp === | ||
+ | |||
+ | Mr. Karp is one of our co-founders and has served in various positions with us since co-founding [[: | ||
+ | |||
+ | === Alexander Moore === | ||
+ | |||
+ | Mr. Moore has served as a member of our Board of Directors since July 2020. Mr. Moore initially joined us in February 2005 as one of the founding employees and served as our director of operations until March 2010. In February 2013, Mr. Moore co-founded [[: | ||
+ | |||
+ | === Alexandra Schiff === | ||
+ | |||
+ | Ms. Schiff has served as a member of our Board of Directors since July 2020. Ms. Schiff worked as a reporter for The Wall Street Journal from June 2004 to March 2005 and April 2013 to June 2020. From 2006 to 2009, she served as a staff writer and then contributing editor at Condé Nast Portfolio, a magazine that was formerly part of [[:Condé Nast]], a global media company. She has written for publications including The [[:New York Times]], [[:Vanity Fair]], and [[: | ||
+ | |||
+ | === Stephen Cohen === | ||
+ | |||
+ | Mr. Cohen is one of our co-founders and has served in various positions with us since co-founding [[: | ||
+ | |||
+ | === Peter Thiel === | ||
+ | |||
+ | Mr. Thiel is one of our co-founders and has served as the Chairman of our Board of Directors since 2003. He has served as president of Thiel Capital, an investment firm, since 2011 and as a partner of [[:Founders Fund]], a venture capital firm, since 2005. In 1998, Mr. Thiel co-founded [[: | ||
+ | |||
+ | === Lauren Friedman Stat === | ||
+ | |||
+ | Ms. Stat has served as a member of our Board of Directors since January 2021. Ms. Stat brings a wide range of business and leadership experience, including 15 years of experience at Accenture, from October 2005 to January 2021, where she served as a senior advisor to Fortune 100 companies, helping her clients develop new strategies, optimize operations, and manage large-scale change. During her tenure at [[: | ||
+ | |||
+ | Ms. Stat has served on the board of directors of The Lorelton, a non-profit retirement and assisted living facility since December 2021 and Tree3, a startup empowering influencers to curate a storefront from millions of products across stores and allow their followers to purchase from a single shopping cart since January 2022, and has served as Chairwoman of the board of directors of [[: | ||
+ | |||
+ | === Eric Woersching === | ||
+ | |||
+ | Mr. Woersching has served as a member of our Board of Directors since June 2022. Mr. Woersching currently serves as a private consultant for early stage software companies, where he focuses on corporate strategy, FP&A, analytics, operations and executive recruiting. From 2020 to 2022, Mr. Woersching served as the Vice President of Revenue Operations at [[: | ||
+ | |||
+ | ==== NEWS ==== | ||
+ | |||
+ | Peter Thiel joins board of antibody therapy developer AbCellera | ||
+ | |||
+ | Reuters - November 19, 2020 | ||
+ | |||
+ | (Reuters) - Billionaire venture capitalist [[:Peter Thiel]] has joined AbCellera Biologics Inc’s board of directors, the Canadian antibody therapy developer said on Thursday. | ||
+ | |||
+ | Thiel, who has backed several startups as they went public, is an existing investor in AbCellera. He joins the startup’s board a couple of months after Reuters reported that it had hired investment banks for a U.S. initial public offering, which could come this year. | ||
+ | |||
+ | AbCellera has been working with [[:Eli Lilly]] and Co LLY.N to **develop a treatment for the novel coronavirus**. | ||
+ | |||
+ | Thiel is known for his early investments in [[: | ||
+ | |||
+ | ===== External links ===== | ||
+ | |||
+ | * [[https:// |